University of Iowa Research Foundation Patent applications |
Patent application number | Title | Published |
20160122762 | METHODS OF TREATING ATHEROSCLEROSIS - Certain embodiments of the invention provide a method of treating endothelial dysfunction, cardiovascular disease and/or atherosclerosis in a mammal, comprising administering an effective amount of a micro-RNA-204-5p inhibitor to the mammal. | 05-05-2016 |
20160120934 | LUNG INJURY REPAIR COMPOSITIONS AND METHODS - The present invention provides a pharmaceutical composition comprising Protein Kinase C Zeta (PKC-ζ) inhibitor and therapeutic methods for preventing or treating a pathological condition or symptom or for inducing proliferation of lung progenitor cells in a mammal by administering the PKC-ζ inhibitor. | 05-05-2016 |
20160108406 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING - The present invention relates to methods of reducing ΔF508-CFTR ubiquitination or degradation, or increasing ΔF508-CFTR processing or function in a CF cell comprising contacting the cell with a therapeutic agent that inhibits NEDD8, FBXO2, and/or SYVN1 expression in the cell. | 04-21-2016 |
20160108403 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 04-21-2016 |
20160095837 | MODULATION OF MITOCHONDRIAL CALCIUM UNIPORTER ACTIVITY FOR TREATING AND PREVENTING ARRHYTHMIAS - Disclosed are methods and compositions for treating or preventing diseases or disorders associated with mitochondrial calcium uniporter (MCU) activity. The methods may include administering a modulator of MCU activity to a patient in need thereof. | 04-07-2016 |
20160090597 | METHODS TO PREVENT AND TREAT AUTOSOMAL DOMINANT NON-SYNDROMIC HEARING LOSS - The present invention provides in certain embodiments a method of treating autosomal dominant non-syndromic hearing loss (ADNSHL) in a patient in need thereof comprising: (a) identifying a mutation in an ADNSHL-causing gene, (b) preparing a ADNSHL therapeutic miRNA, and (c) administering to the patient a pharmaceutical composition comprising the ADNSHL therapeutic miRNA and a pharmaceutically acceptable carrier. | 03-31-2016 |
20160060624 | HUNTINGTON'S DISEASE THERAPEUTIC COMPOUNDS - The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease. | 03-03-2016 |
20160038521 | THERAPEUTIC METHODS - Certain embodiments of the present invention provide a method for treating or preventing juvenile neuronal ceroid lipofuscinosis (JNCL) in an animal comprising administering CBX, GRA, or GZA to the animal. | 02-11-2016 |
20160035088 | AUTOMATED SEPARATION OF BINARY OVERLAPPING TREES - Provided are systems and methods for analyzing images. An exemplary method can comprise receiving at least one image having one or more annotations indicating a feature. The method can comprise generating training images from the at least one image. Each training image can be based on a respective section of the at least one image. The training images can comprise positive images having the feature and negative images without the feature. The method can comprise generating a feature space based on the positive images and the negative images. The method can further comprise identifying the feature in one or more unclassified images based upon the feature space. | 02-04-2016 |
20160022837 | PROMOTER COMPOSITIONS - An isolated promoter sequence comprising a nucleic acid of between 600 and 1700 nucleotides in length having at least 90% identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. | 01-28-2016 |
20150374781 | METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain. | 12-31-2015 |
20150366884 | COMPOSITIONS AND METHODS FOR CANCER THERAPY - The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier. | 12-24-2015 |
20150329461 | METHODS FOR SEPARATING MIXTURES OF FATTY ACIDS - The invention provides methods for separating mixtures of two or more fatty acids. | 11-19-2015 |
20150322099 | THERAPEUTIC BISPHOSPHONATES - The invention provides novel pyrophosphate synthase inhibitors of formula I and formula II as well salts thereof; the invention also provides compositions comprising such inhibitors and methods for their use. | 11-12-2015 |
20150313924 | METHODS OF IMPROVING RNAI IN WELL-DIFFERENTIATED AIRWAY EPITHELIA - The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a facilitating agent followed by contacting the cell with a therapeutic RNAi agent, wherein the facilitating agent comprises a Platelet-activating factor receptor (PAFR) ligand. | 11-05-2015 |
20150224066 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - The disclosure relates to antibiotic compositions and methods of use thereof in a mammal. In certain embodiments, the present invention provides an antimicrobial composition comprising a non-aqueous carrier and an active agent, wherein the active agent is menadione, 1,4-naphthoquinone, Coenzyme Q1, Coenzyme Q2, Coenzyme Q3, Coenzyme Q4, Coenzyme Q5, Coenzyme Q6, Coenzyme Q7, Coenzyme Q8, Coenzyme Q9, and/or Coenzyme Q10, or a pharmaceutically acceptable salt thereof. | 08-13-2015 |
20150210664 | THERAPEUTIC COMPOUNDS - The invention provides compounds useful as anti-cancer agents. | 07-30-2015 |
20150182740 | CATHETERS, CATHETER SYSTEMS, AND METHODS FOR PUNCTURING THROUGH A TISSUE STRUCTURE - A percutaneous catheter system for use within the human body and an ablation catheter for ablating a selected tissue region within the body of a subject. The percutaneous catheter system can include two catheters thai are operatively coupled to one another by magnetic coupling through a tissue structure. The ablation catheter can include electrodes positioned within a central portion. The ablation catheter is positioned such that the central portion of a flexible shaft at least partially surrounds the selected tissue region. Each electrode of the ablation catheter can be activated independently to apply ablative energy to the selected tissue region. The ablation catheter can employ high impedance structures to change the current density at specific points. Methods of puncturing through a tissue structure using the percutaneous catheter system are disclosed. Also disclosed are methods for ablating a selected tissue region using the ablation catheter. | 07-02-2015 |
20150141893 | CLUBFOOT ORTHOTIC - Devices and methods for treating clubfoot are disclosed. | 05-21-2015 |
20150132783 | Neuroprotective Chemicals and Methods for Identifying and Using Same - Provided herein are methods for identifying a compound having cell-protective (e.g., neuroprotective) activity. Compounds identified therefrom are also provided. These compounds can be used to treat various diseases, disorders, or conditions associated with, for example, unwanted cell death. | 05-14-2015 |
20150093802 | ZINC FINGER NUCLEASE FOR THE CFTR GENE AND METHODS OF USE THEREOF - The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene. | 04-02-2015 |
20150050646 | Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration - Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm. | 02-19-2015 |
20140379043 | MANAGING BACK PAIN BY APPLYING A HIGH FREQUENCY ELECTRICAL STIMULUS DIRECTLY TO THE SPINAL CORD - This invention provides a new technology for management of back pain by stimulating the spinal cord in a manner that renders it refractory to transmission of deleterious or undesirable sensory input. The electrical stimulus comprises high frequency pulses in a regular or complex pattern or that are stochastically produced under microprocessor control. The stimulus is applied directly to the surface of the spinal cord from within the spinal canal, which provides important benefits over previous technology. The stimulus alleviates symptoms and signs of back pain, while minimizing the risk of side effects such as paresthesia, and potentially minimizing the effects on motor neuron transmission and proprioception. | 12-25-2014 |
20140371188 | COMPOSITIONS AND METHODS FOR INHIBITING MUSCLE ATROPHY AND INDUCING MUSCLE HYPERTROPHY - In an aspect, the invention relates to compositions, methods, and kits for inhibiting or preventing skeletal muscle atrophy or inducing muscle hypertrophy by providing to an animal an effective amount of a composition comprising a Gadd45a and/or Cdkn1a inhibitor and an androgen and/or growth hormone elevator or an androgen and/or growth hormone receptor activator. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 12-18-2014 |
20140323473 | COMPOUNDS AND METHODS TO TREAT ORGANOPHOSPHORUS POISONING - Organophosphate (OP) nerve agents and pesticides are potent inhibitors of acetylcholinesterase (AChE). Though oxime nucleophiles can reactivate an AChE-phosphyl adduct, the adduct can undergo a reaction called aging, leading to an aged-AChE adduct. The invention provides compounds and methods that can be used to reactivate an aged-AChE adduct. Such compounds and methods are useful to counteract organophosphorus poisoning. | 10-30-2014 |
20140309620 | TRANSILLUMINATING OBTURATOR - Methods and devices for placement of a medical device using illumination are disclosed. | 10-16-2014 |
20140303362 | REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity. | 10-09-2014 |
20140303199 | INHIBITORS OF RGS PROTEINS - G-protein coupled receptors are a diverse group that are the target of over 50% of marketed drugs. Activation of these receptors results in the exchange of bound GDP for GTP in the Gα subunit of the heterotrimeric G-protein. The Gα subunit dissociates from the β/γ subunits and both proceed to affect downstream signaling targets. The signal terminates by the hydrolysis of GTP to GDP and is regulated by Regulators of G-protein Signaling (RGS) proteins that act as GTPase Activating Proteins (GAPs). This makes RGS proteins potentially desirable targets for “tuning” the effects of current therapies as well as developing novel pharmacotherapies. The present invention provides a convenient assay for identifying modulators of RGS proteins that can be adapted for high throughput screening utilizing the colorimetric dye, malachite green, to detect free phosphate in the presence of a test compound. | 10-09-2014 |
20140296099 | Use of MicroRNA for Assessing Embryos Grown in Vitro and Improving Culture Media - Disclosed are methods of detecting miRNA expression by an embryo. The methods may be utilized for assessing embryo viability and chromosomal makeup and selecting the embryo for subsequent implantation into a patient. The methods also may be utilized for modifying and optimizing culture media to improve embryo viability via adding one or more miRNAs to culture media for the embryo or depleting one or more miRNAs from the culture media for the embryo. Kits for performing the disclosed methods are also disclosed. | 10-02-2014 |
20140287492 | RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 09-25-2014 |
20140275964 | MARKER-FLANGE FOR MRI-GUIDED BRACHYTHERAPY - Disclosed herein is a marker flange for use with a brachytherapy applicator, having a flange body with a first face, a second face, and a hollow chamber positioned between the first and second faces. A cavity extending through the flange body is dimensioned to receive a tandem in a brachytherapy applicator in a press-fit connection, so as to affix the flange-marker to an outside surface of the tandem. The hollow chamber includes an MR imaging responsive marker agent that provides strong signal intensities and a high geometric accuracy in MR imaging. | 09-18-2014 |
20140271565 | FLUORAPATITE GLASS-CERAMICS - The present invention provides a highly-sintered fluorapatite glass-ceramic comprising a high Ca/Al or Sr/Al mole-ratio, that possesses a microstructure that induces apatite/bone deposition. | 09-18-2014 |
20140249406 | COMPENSATOR-BASED BRACHYTHERAPY - Compensator-based brachytherapy (CBT) for treatment of cancerous tumors or other pathologic tissues. CBT permits, in one aspect, increased dosage conformity for non-radially symmetric tumors by utilizing a device that can shield radiation emanated from an electronic brachytherapy (BT) source or non-electronic BT source. The device can comprise, in one aspect, a radiation compensator having a treated surface that comprises a position-dependent thickness based at least on a radiation therapy plan specific to a patient and geometry of a patient region to be treated. In an additional or alternative aspect, the device can comprise a source of radiation movably inserted into an enclosure coupled to the radiation compensator. As part of CBT, in one implementation, the radiation source can reside at a plurality of locations within the radiator compensator during a respective plurality of dwell times based on the radiation therapy plan. | 09-04-2014 |
20140199245 | OLIGONUCLEOTIDE-BASED PROBES FOR DETECTION OF BACTERIAL NUCLEASES - The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., ribonuclease) substrates, and probes and compositions useful in detection assays. Accordingly, in certain embodiments, the present invention provides a probe for detecting a microbial endonuclease comprising a substrate oligonucleotide of 2-30 nucleotides in length, a fluorescence-reporter group operably linked to the oligonucleotide, and a fluorescence-quencher group operably linked to the oligonucleotide. The fluorescence-reporter group and the fluorescence-quencher group are separated by at least one RNAse-cleavable residue, e.g., RNA base. | 07-17-2014 |
20140179003 | ALTERNATIVE EXPORT PATHWAYS FOR VECTOR EXPRESSED RNA INTERFERENCE - The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules. | 06-26-2014 |
20140163214 | RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules. | 06-12-2014 |
20140161777 | METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain. | 06-12-2014 |
20140148503 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 05-29-2014 |
20140142288 | THERAPEUTIC COMPOUNDS - The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease. | 05-22-2014 |
20140134204 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing antibody response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 05-15-2014 |
20140128955 | REMOTELY CONTROLLED AND/OR LATERALLY SUPPORTED DEVICES FOR DIRECT SPINAL CORD STIMULATION - A method for treating intractable pain via electrical stimulation of the spinal cord. Remote, non-contact stimulation of a selected region of spinal cord is achieved by placement of a transceiver patch directly on the surface of that region of spinal cord, with said patch optionally being inductively coupled to a transmitter patch of similar size on either the outer or inner wall of the dura surrounding that region of the spinal cord. By inductively exchanging electrical power and signals between said transmitter and transceiver patches, and by carrying out the necessary electronic and stimulus signal distribution functions on the transceiver patch, the targeted dorsal column axons can be stimulated without the unintended stray stimulation of nearby dorsal rootlets. Novel configurations of a pliable surface-sheath and clamp or dentate ligament attachment features which realize undamaging attachment of the patch to the spinal cord are described. | 05-08-2014 |
20140128730 | SYSTEMS AND METHODS FOR COMPUTED TOMOGRAPHIC RECONSTRUCTION - An image of an object is synergistically reconstructed using two or multiple imaging modalities. A first reconstructed image, showing structural information of the object is produced using a first imaging modality. The first reconstructed image is segmented, and known optical properties of the object are then mapped to the first reconstructed image. Optical signal emissions from the object are detected and registered with the first reconstructed image. A second reconstructed image volume is then produced using a second imaging modality, based on the mapped optical properties after registration between the first image and the data from the second modality. The second reconstructed image depicts some optical property, such as a bioluminescent source distribution, or optical properties, such as, attenuation and scattering properties, of the object. | 05-08-2014 |
20140127253 | BIODEGRADABLE PARTICULATE FORMULATIONS - The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant. | 05-08-2014 |
20140099506 | Biodegradable Polymers with Sulfenamide Bonds for Drug Delivery Applications - The present invention provides polysulfenamides and methods of making same. | 04-10-2014 |
20140088179 | METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides methods of treating a disease in a non-rodent mammal comprising administering to the cerebrospinal fluid (CSF) of the non-rodent mammal an rAAV2 particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner effective to infect an ependymal cell in the non-rodent mammal, wherein the ependymal cell secretes the therapeutic protein so as to treat the disease. | 03-27-2014 |
20140081240 | METHOD OF DELIVERING VECTORS TO PANCREAS AND LUNGS BY CANNULATING THE AORTA - The present invention relates to a safe and effective way to deliver and express therapeutic compositions (e.g., transgenes) to the pancreas and lungs of a mammal. | 03-20-2014 |
20140066388 | MITOCHONDRIAL-TARGETED CATIONIC NANOPARTICLES COMPRISING CAMKII INHIBITORS AND USES THEREOF FOR TREATING AND PREVENTING DISEASES AND DISORDERS ASSOCIATED WITH CAMKII ACTIVITY - Disclosed are compositions and methods for treating or preventing diseases or disorders associated with mitochondrial CaMKII activity. | 03-06-2014 |
20140056959 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 02-27-2014 |
20140052030 | SYSTEM TO APPLY MECHANICAL AND PHYSIOLOGICAL THERAPEUTIC STRESS TO ANIMAL AND HUMAN TISSUE - A method and apparatus for stimulating the tissue of an animal. The apparatus can comprise a vibration system configured to apply a vibration to the tissue. The apparatus can also comprise a compression system configured to compress the tissue. The system can deliver combinations of compressive or vibration stress to tissue either with or without background muscle contractions. | 02-20-2014 |
20140038231 | ISOLATION AND CHARACTERIZATION OF TUMOR CELLS USING SHEAR STRESS MEASUREMENTS - Methods for isolating viable cancer cells from a sample that comprises a mixture of cancerous cells and normal (non-cancerous) cells are provided. In the methods, a fluid preparation comprising a mixture of cancerous and normal cells is repeatedly exposed to fluid shear stresses, whereby the repeated exposure to the fluid shear stresses preferentially imparts fluid shear stress-resistance to the cancerous cells. | 02-06-2014 |
20140035909 | SYSTEMS AND METHODS FOR GENERATING A THREE-DIMENSIONAL SHAPE FROM STEREO COLOR IMAGES - This disclosure presents systems and methods for determining the three-dimensional shape of an object. A first image and a second image are transformed into scale space. A disparity map is generated from the first and second images at a coarse scale. The first and second images are then transformed into a finer scale, and the former disparity map is upgraded into a next finer scale. The three-dimensional shape of the object is determined from the evolution of disparity maps in scale space. | 02-06-2014 |
20140005202 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient | 01-02-2014 |
20130316022 | METHOD TO ENHANCE ANTIMICROBIAL ACTIVITY BY INCREASING pH - The invention provides a method to enhance antimicrobial activity, e.g., in a mammal. | 11-28-2013 |
20130303454 | LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF - Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus. | 11-14-2013 |
20130301889 | OPTIMAL, USER-FRIENDLY, OBJECT BACKGROUND SEPARATION - A method of identifying an object of interest can comprise obtaining first samples of an intensity distribution of one or more object of interest, obtaining second samples of an intensity distribution of confounder objects, transforming the first and second samples into an appropriate first space, performing dimension reduction on the transformed first and second samples, whereby the dimension reduction of the transformed first and second samples generates an object detector, transforming one or more of the digital images into the first space, performing dimension reduction on the transformed digital images, whereby the dimension reduction of the transformed digital images generates one or more reduced images, classifying one or more pixels of the one or more reduced images based on a comparison with the object detector, and identifying one ore more objects of interest from the classified pixels. | 11-14-2013 |
20130281372 | METHODS TO ENHANCE RNAI OLIGONUCLEOTIDE DELIVERY TO RESPIRATORY EPITHELIAL CELLS - The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent. | 10-24-2013 |
20130252909 | TANNIN INHIBITORS OF HIV - The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins. | 09-26-2013 |
20130225517 | Therapeutic Compounds - The invention provides compounds of formula I: | 08-29-2013 |
20130220034 | PERSONAL NANOPARTICLE RESPIRATORY DEPOSITIONS SAMPLER AND METHODS OF USING THE SAME - A personally portable nanoparticle respiratory deposition (NRD) sampler configured to collect nanoparticles based upon a sampling criterion. In an aspect, the NRD sampler has an impactor stage, and a diffusion stage. In another aspect, the NRD sampler includes a particle size separator in addition to an impactor stage and a diffusion stage. | 08-29-2013 |
20130210708 | METHODS OF INHIBITING AND TREATING BACTERIAL BIOFILMS BY METAL CHELATORS - The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. | 08-15-2013 |
20130203712 | METHODS FOR INHIBITING MUSCLE ATROPHY - In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 08-08-2013 |
20130142764 | METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain. | 06-06-2013 |
20130129719 | HER2 NUCLEIC ACID APTAMERS - The present invention relates to optimized HER2 aptamers and methods of using these aptamers. | 05-23-2013 |
20130108131 | Methods And Systems For Determining Optimal Features For Classifying Patterns Or Objects In Images | 05-02-2013 |
20130065298 | siRNA-MEDIATED GENE SILENCING - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 03-14-2013 |
20130065296 | BACULOVIRUSES WITH ENHANCED VIRION PRODUCTION AND A METHOD FOR THE PRODUCTION OF BACULOVIRUSES - A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein. | 03-14-2013 |
20130034496 | POSITRON EMISSION TOMOGRAPHY TRACER - The present invention relates to positron emission tomography tracers and methods of using these tracers. | 02-07-2013 |
20130033739 | ELECTROVARIABLE NANOPLASMONICS AND SELF-ASSEMBLING SMART MIRRORS - Systems and methods provide control of nanoparticle coverage of an interface between a first medium and a second medium through variation of an electric potential across such interface; the first medium and the second medium are immiscible media, and transparent or substantially transparent to visible light. The first medium can be a first electrolytic solution and the second medium can be a second electrolytic solution; thus, the interface can become an interface of two immiscible electrolytic solutions (ITIES). The nanoparticle coverage of the interface, e.g., the ITIES, can be regulated to vary between approximately zero and a full or nearly a full monolayer. The nanoparticle coverage of the interface can dictate at least one optical property of the interface, rendering the interface transparent or substantially transparent, or a mirror, or providing Faraday rotation of the optical polarization of light incident normal to the interface and propagating through the interface. | 02-07-2013 |
20130020262 | HIGH-DENSITY POLYDICYCLOPENTADIENE - The invention provides highly cross-linked polydicyclopentadiene matrices and methods for using such matrices to separate components having varying cross-sectional areas. | 01-24-2013 |
20130018308 | BIOFEEDBACK TRAINING OF ANAL AND RECTAL MUSCLES - A probe including a housing, a rectal muscle air bag, a rectal tube, an anal muscle air bag, and an anal tube is provided. The rectal muscle air bag mounts to the housing a first distance from a non-insertion end. A rectal tube is connected to the rectal muscle air bag at a first end and to a first pressure sensor at a second end. The anal muscle air bag is mounted to the housing a second distance from the non- insertion end. The anal tube is connected to the anal muscle air bag at a first end and to a second pressure sensor at a second end. The first distance is selected to position the rectal muscle air bag adjacent a rectal muscle, and the second distance is selected to position the anal muscle air bag adjacent an anal muscle when the housing is inserted in the rectum. | 01-17-2013 |
20130012568 | Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy. | 01-10-2013 |
20120297495 | ZINC-FINGER NUCLEASE AND RNA INTERFERENCE MEDIATED INACTIVATION OF VIRAL GENOMES - Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus. | 11-22-2012 |
20120283424 | REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity. | 11-08-2012 |
20120277323 | CELLULOSE CAPSULES AND METHODS FOR MAKING THEM - Disclosed are cellulose capsules, methods for preparing a cellulose capsule, and compositions comprising cellulose capsules, including sustained- or controlled-release dosage forms comprising cellulose capsules. | 11-01-2012 |
20120195926 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing anti-body response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 08-02-2012 |
20120142583 | Methods of inhibiting and treating bacterial biofilms by metal chelators - The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. | 06-07-2012 |
20120108514 | LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF - Materials and Methods related to making and using natriuretic polypeptides having a mutation that results in an extended carboxy terminus. | 05-03-2012 |
20120095089 | SCHWEINFURTHINS AND USES THEREOF - Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a schweinfurthin or schweinfurthin analog or derivative, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Also disclosed is a new schweinfurthin compound of the formula. | 04-19-2012 |
20120071356 | Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration - Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided. | 03-22-2012 |
20120069299 | HYBRID LASER OPHTHALMOSCOPE - Provided is a hybrid laser ophthalmoscope comprising a laser light source, a LED light source, and a holographic diffuser, wherein the holographic diffuser is configured to shape a beam of light into a Maxwellian ring. | 03-22-2012 |
20120040884 | Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration - Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm. | 02-16-2012 |
20120035320 | POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES - The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes. | 02-09-2012 |
20120027673 | SYNTHESIS OF HIERARCHICAL NANOCRYSTALLINE ZEOLITES WITH CONTROLLED PARTICLE SIZE AND MESOPOROSITY - A one step synthesis of nanocrystalline zeolites ZSM-5 and Naβ from a single template system in high yield has been discovered. The size of individual nanocrystals, as well as mesopore surface area and pore volume can be controlled by adjusting the pH of the reaction mixture, as well as the hydrothermal treatment temperature and duration. The mesopore volume and size distribution show a dependence on particle size such that smaller particles lead to higher mesopore volumes and narrower pore size distributions. | 02-02-2012 |
20120015396 | COMPOSITIONS AND METHODS FOR MODULATING THE ACID-SENSING ION CHANNEL (ASIC) - Novel compositions for modulating acid-sensing ion channels (ASIC) function comprising ASICα, ASICβ, and BNC1 and derivatives thereof; methods for modulating ASIC function and methods for treating cognitive disorders and for memory enhancement using the novel compositions of the invention; and a method for increasing synaptic plasticity are described. | 01-19-2012 |
20120014875 | NUCLEIC ACID APTAMERS - The present invention relates to optimized aptamers and methods of using these aptamers. | 01-19-2012 |
20110319481 | SCHWEINFURTHIN ANALOGUES - Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs. | 12-29-2011 |
20110318735 | REGULATION OF THE SEROTONIN REUPTAKE TRANSPORTER AND DISEASE - Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity. | 12-29-2011 |
20110301580 | METHODS AND DEVICES FOR ARYTENOID REPOSITIONING - Methods and devices for repositioning the arytenoid cartilage of a human subject are disclosed. | 12-08-2011 |
20110260278 | System and Method of Planar Processing of Semiconductors into Detector Arrays - An article of manufacture and a method of defining a photodetector element are provided. The article of manufacture includes a photodector element comprising a junction formed by a first III-V semiconductor layer having a first charge type and a second III-V semiconductor layer comprising a second dopant having a second charge type. The second III-V semiconductor layer is disposed between the first III-V semiconductor layer and a wafer. Patterned dopant regions having a third charge type, the third charge type being the same as the first charge type, are disposed in the first III-V semiconductor layer. | 10-27-2011 |
20110253151 | POSITIONING DEVICE FOR ANKLE JOINT REPLACEMENT SURGERY - A positioning device for ankle joint replacement surgery. | 10-20-2011 |
20110244562 | RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules. | 10-06-2011 |
20110244561 | siRNA-MEDIATED GENE SILENCING - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 10-06-2011 |
20110237645 | USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3 - In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844 or miR847, were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral (HSV-1) vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the present invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like. | 09-29-2011 |
20110212520 | RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 09-01-2011 |
20110207190 | METHODS OF XYLITOL PREPARATION - The invention provides spray-dried preparations of microbes useful for oxidoreductase reactions, e.g., xylitol production, and methods of making and using those microbes. | 08-25-2011 |
20110206773 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye. | 08-25-2011 |
20110182908 | Diagnostics and Therapeutics for Macular Degeneration-Related Disorders - The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders. | 07-28-2011 |
20110166687 | METHOD FOR DETERMINING THE PRODUCTION PARAMETERS FOR A SUBSTRATE COATING PROCESS - A method to evaluate, determine and optimize production parameters for a coating application of a UV cationic polymerizable coating system to a substrate is provided. The method is based on a simulation model which includes both shadow and dark cure processes. Both of an active center generation process and the active center diffusion process are mathematically described. In the model, the two processes are considered separately since they are driven by different fundamental phenomena and occur on different timescales. Evaluation or prediction of the effect of process variables on the curing of a cationic coating of a complex substrate according to the described method allows characterization and understanding of process variables which may save set-up costs and improve production efficiency. | 07-07-2011 |
20110166081 | Alpha-dystroglycan as a Protein Therapeutic - Disclosed is alpha-dystroglycan protein (alpha-DG) in glycosylated and functional form. The disclosed alpha-DG binds to the basal lamina and to the sarcolemma of muscle fibers and may be injected into muscle and incorporated into muscle fibers in order to restore membrane integrity where the muscle fibers comprise a dysfunctional alpha-DG protein. Alpha-DG as disclosed herein may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with or characterized by a dysfunctional alpha-DG, such as muscular dystrophy. | 07-07-2011 |
20110160297 | SCHWEINFURTHIN ANALOGUES - The invention provides fluorescent schweinfurthin analogs of formula(I) which are useful as probes and for the treatment of cancer and other diseases. | 06-30-2011 |
20110160219 | Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient - Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors. | 06-30-2011 |
20110152172 | Methods of Treating Pulmonary Diseases and Disorders by Modulating Calcium/Calmodulin Dependent Protein Kinase II Activity - Disclosed are methods of treating or preventing a pulmonary disease or disorder in a subject, the methods comprising administering an effective amount of an compound that inhibits Calmodulin Kinase II (CaMKII) activity, either directly or indirectly, thereby treating or preventing the pulmonary disease or disorder in the subject. | 06-23-2011 |
20110135689 | Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis - The present invention is directed to compounds and methods for treating a mammal exposed to | 06-09-2011 |
20110111491 | RNA INTERFERENCE SUPPRESION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 05-12-2011 |
20110081366 | IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES - Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant. | 04-07-2011 |
20110059265 | METHOD FOR PRODUCING LAYERED MATERIALS USING LONG-LIVED PHOTO-INDUCED ACTIVE CENTERS - The invention relates to a method for applying a photo-activated layered polymer coating to a substrate material in which one or more layers do not contain photoinitiator, or are not exposed to initiating light, but cure due to migration of cationic active centers. At least two separate monomer layers are applied to the substrate material. At least one of the monomer layers includes a photoinitiator capable of producing cationic active centers. The at least one layer including the photoinitiator is exposed to a source of UV radiation at a desired wavelength forming cationic active centers. The at least two separate monomer layers react in a polymerization reaction forming a cured layered material. The cationic active centers of the exposed monomer layer migrate to the unexposed layer such that both layers cure via the polymerization reaction. | 03-10-2011 |
20110054247 | METHODS FOR CLONING FERRETS AND TRANSGENIC FERRET MODELS FOR DISEASES - The invention provides a transgenic Mustelidae in which a gene associated with a human disease or condition comprises a targeted genetic modification, and uses thereof. Also provided is a method to cryopreserve Mustelidae embryos or cells, and to enhance the number of live offspring from cryopreserved Mustelidae embryos. | 03-03-2011 |
20110033421 | METHODS RELATED TO IMMUNOSTIMULATORY NUCLEIC ACID-INDUCED INTERFERON - Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs. | 02-10-2011 |
20100330630 | SPRAY DRIED MICROBES AND METHODS OF PREPARATION AND USE - The invention provides spray-dried preparations of microbes and methods of using those microbes. | 12-30-2010 |
20100291673 | ALTERNATIVE EXPORT PATHWAYS FOR VECTOR EXPRESSED RNA INTERFERENCE - The present invention is directed to nucleic acid molecules containing a loop sequence designed to circumvent exportin-5 mediated export, and methods using these novel molecules. | 11-18-2010 |
20100248263 | BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 09-30-2010 |
20100240612 | Prenylated Bisphosphonates as Anti-tuberculosis Agents - The invention provides methods to treat a mycobacterium infection and methods to inhibit mycobacterial polyprenyl pyrophosphate synthesis with a compound of formula I. The invention also provides novel compounds of formula I as well as salts and prodrugs thereof. | 09-23-2010 |
20100235936 | ZINC-FINGER NUCLEASE AND RNA INTERFERENCE MEDIATED INACTIVATION OF VIRAL GENOMES - Embodiments of the present invention provide methods for targeted inactivation of viral genomes. In one embodiment, zinc-finger proteins in which DNA binding sites are altered such that they recognize and bind different, desired DNA sequences contained in hepatitis B virus (HBV) and that include nuclease domains are used for inactivation. Other embodiments for targeted inactivation of viral genomes use small nucleic acid molecules, such as short micro-RNA molecules or short hairpin RNA molecules capable of mediating RNA interference (RNAi) against the hepatitis B virus. | 09-16-2010 |
20100227392 | Use of RPA32, RPA4, and RPA4/RPA32 Hybrid Polypeptides and Polynucleotides for Assessing and Modulating Cell Proliferation - Disclosed are polynucleotides and polypeptides that are useful for assessing and modulating cell proliferation. The polynucleotides may comprise coding regions for RPA4 and RPA4/RPA32 hybrid polypeptides. The polynucleotides may be used in gene vectors for modulating cell proliferation in a patient in need thereof. Diagnostic methods related to assaying RPA4 expression in test samples in order to detect proliferating or cancerous cells also are disclosed. | 09-09-2010 |
20100226929 | Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods - Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy. | 09-09-2010 |
20100179330 | Methods for the Preparation of Thiazolidinethione Indene-Based Chiral Auxiliaries - Methods for the preparation of indene-based thiazolidinethiones are provided comprising contacting 1-amino-2,3-dihydro-1H-inden-2-ol, or a substituted derivative thereof, with an acid under suitable reaction conditions to provide a first intermediate; and contacting the first intermediate with an alkali xanthate in the presence of an alkali hydroxide under suitable reaction conditions to provide a compound of formula (III), | 07-15-2010 |
20100148154 | APPARATUS AND SEMICONDUCTOR CO-CRYSTAL - The invention provides a method to enforce face-to-face stacking of organic semiconductors in the solid state that employs semiconductor co-crystal formers (SCCFs), to align semiconductor building blocks (SBBs). Single-crystal X-ray analysis reveals π-orbital overlap optimal for organic semiconductor device applications. | 06-17-2010 |
20100144026 | siRNA-mediated gene silencing with viral vectors - The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors. | 06-10-2010 |
20100081706 | IMMUNOMODULATORY OLIOGONUCLEOTIDES AND METHODS OF USE THEREFOR - The present invention is drawn a new class of oligodeoxynucleotides (ODNs) that inhibit ODN-activation of Toll-like receptor (TLR) 9. Particular 4-5 base extensions at the 5′ and of the previously described core inhibitory ODN sequence enhances their inhibitory activity against human cells expressing human TLR9. Methods of use also are provided. | 04-01-2010 |
20100076061 | REPEATED ADMINISTRATION OF LENTIVIRAL VECTORS TO RESPIRATORY CELLS - The invention provides methods for administering lentiviral vectors to the respiratory system of a patient to treat a disease. | 03-25-2010 |
20100028231 | SYNTHESIS AND USE OF NANOCRYSTALLINE ZEOLITES - Embodiments of the present invention relate to a method for synthesizing nanocrystalline zeolites, the method comprising contacting starting products that comprise a solvent, a silicon source, a cation base, an organic template, and an aluminum source, or any combination thereof sufficient to produce a zeolite gel by hydrolysis, heating the zeolite gel sufficient to produce a first batch of zeolite crystals and a first clear solution, separating the first batch of zeolite crystals from the first clear solution, heating the first clear solution sufficient to produce a second batch of zeolite crystals and second clear solution and separating the second batch of zeolite crystals from the second clear solution. In addition, embodiments relate to a method of using nanocrystalline zeolites, the method comprising contacting a nanocrystalline zeolite with a reductant sufficient to produce a nanocrystalline zeolite with adsorbed reductant and exposing the nanocrystalline zeolite with adsorbed reductant to reactant gases sufficient to obtain reaction products and the nanocrystalline zeolite. | 02-04-2010 |
20100010185 | MODIFIED POLYDICYCLOPENTADIENES - The present invention provides novel, modified polydicyclopentadienes and methods to prepare modified polydicyclopentadienes. The modified polydicyclopentadienes prepared by the methods of the invention are useful in many applications including new and useful solid phases for chromatography. | 01-14-2010 |
20090299102 | APPARATUS AND METHOD FOR CARRYING OUT MULTIPLE REACTIONS - The invention provides methods and an apparatus useful for site-isolating reagents or catalysts during chemical reactions. The methods and apparatus are useful for carrying out cascade or domino reactions. | 12-03-2009 |
20090291150 | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING SEIZURES BY MODULATING ACID-SENSING ION CHANNEL ACTIVITY - This invention provides novel methods and compositions for treating and preventing seizures by administration of ASIC1a receptor activating compounds. A novel method of assaying ASIC1a receptor activating compounds is included in the present invention. According to the invention applicants have demonstrated that seizure duration, intensity, and progression may be modulated by administration of an ASIC1a receptor activator which acts to increase the endogenous activity of ASIC1a receptors to mediate the effects of low pH in the CNS. The inventors have also found that the ASIC1a receptor activator may prevent such seizures altogether. | 11-26-2009 |
20090258822 | Diagnosis and Treatment of Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 10-15-2009 |
20090257723 | FIBERSCOPES AND FIBER BUNDLES - An elongate imaging fiber bundle may include a plurality of elongate optical fibers coherently arranged in the bundle, the plurality including peripheral fibers at a periphery of the bundle and deep fibers deep to the peripheral fibers, and a coating surrounding the plurality of fibers. An exposed length of the bundle, intermediate the bundle's proximal and distal ends, may be chemically etched to be denuded of the coating, and peripheral fibers are so severed as to permit injection of light into the peripheral fibers at the exposed length. A fiberscope may include a fiber bundle having an exposed length that is denuded of the coating, and peripheral fibers are so severed in the exposed length as to permit injection of light into the peripheral fibers at the exposed length, and a light source so positioned with respect to the exposed length of the bundle as to inject light into the peripheral fibers at the exposed length. | 10-15-2009 |
20090247451 | Therapeutic Compositions for Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 10-01-2009 |
20090241206 | METHODS FOR CLONING FERRETS AND TRANSGENIC FERRET MODELS FOR DISEASES - The invention provides a transgenic Mustelidae in which a gene associated with a human disease or condition comprises a targeted genetic modification, and uses thereof. Also provided is a method to cryopreserve Mustelidae embryos or cells, and to enhance the number of live offspring from cryopreserved Mustelidae embryos. | 09-24-2009 |
20090202575 | IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES - Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. | 08-13-2009 |
20090191188 | IMMUNOSTIMULATORY NUCLEIC ACIDS - The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids. | 07-30-2009 |
20090124542 | METHODS AND REAGENTS FOR TREATMENT AND DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 05-14-2009 |
20090105169 | ALLELE-SPECIFIC SILENCING OF DISEASE GENES - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 04-23-2009 |
20080318264 | Biomarkers Associated With Age-Related Macular Degeneration - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 12-25-2008 |
20080305273 | METHOD OF APPLYING POLYMER COATING TO A SUBSTRATE - An object of complex three-dimensional configuration, such as an automotive vehicle body, is coated with a combination of a coating formulation and a photoactivated mixture containing active centers that have been produced prior to application. The two liquids can be intimately mixed prior to application to the object, or the coating formulation can be applied prior to the application of the photoactivated mixture. The coating formulation is cured by the active centers that have been produced prior to application. | 12-11-2008 |
20080280825 | Protective complement proteins and age-related macular degenration - Methods for identifying a subject at risk for developing AMD are disclosed. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material. Therapeutic compositions and methods are also provided for delaying the progression or onset of the development of AMD in a subject, including treating a subject having signs and/or symptoms of AMD or who has been diagnosed with AMD. | 11-13-2008 |
20080274989 | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof - The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules. | 11-06-2008 |
20080274453 | Diagnostics and therapeutics for macular degeneration - The invention relates to diagnostics and therapeutics and animal models for macular degeneration, specifically as they relate to the association described herein between macular degeneration and arterial wall disruptive disorders. In one embodiment, the invention provides kits and methods for diagnosing macular degeneration comprising identifying a marker for an arterial wall disruptive disorder, including an aneurysm. In one embodiment, the invention provides therapeutics for treating macular degeneration comprising delivering to a subject an agent useful for treating an arterial wall disruptive disorder, including an aneurysm. | 11-06-2008 |
20080249050 | Compounds and methods to enhance rAAV transduction - Agents and methods to alter rAAV transduction are provided. | 10-09-2008 |